{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:23:01Z","timestamp":1707524581728},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,13]]},"DOI":"10.7759\/cureus.26830","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T06:11:42Z","timestamp":1657779102000},"source":"Crossref","is-referenced-by-count":0,"title":["Factors Explaining the Coincidence of Smoldering Multiple Myeloma and Primary Biliary Cholangitis: A Case Report"],"prefix":"10.7759","author":[{"given":"Mirna","family":"El Dirani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julius M","family":"Nagaratnam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samer","family":"Kholoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian D","year":"2016","unstructured":"Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016, 43:676-81. 10.1053\/j.seminoncol.2016.11.004","journal-title":"Semin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0141","article-title":"Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment","volume":"25","author":"Ludwig H","year":"2020","unstructured":"Ludwig H, Novis Durie S, Meckl A, Hinke A, Durie B. Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment. Oncologist. 2020, 25:e1406-13. 10.1634\/theoncologist.2020-0141","journal-title":"Oncologist"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-520890","article-title":"Smoldering multiple myeloma requiring treatment: time for a new definition?","volume":"122","author":"Dispenzieri A","year":"2013","unstructured":"Dispenzieri A, Stewart AK, Chanan-Khan A, et al.. Smoldering multiple myeloma requiring treatment: time for a new definition?. Blood. 2013, 122:4172-81. 10.1182\/blood-2013-08-520890","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.10.018","article-title":"Factors associated with prevalence and treatment of primary biliary cholangitis in United States health systems","volume":"16","author":"Lu M","year":"2018","unstructured":"Lu M, Li J, Haller IV, et al.. Factors associated with prevalence and treatment of primary biliary cholangitis in United States health systems. Clin Gastroenterol Hepatol. 2018, 16:1333-41.e6. 10.1016\/j.cgh.2017.10.018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-3-1","article-title":"Primary biliary cirrhosis","volume":"3","author":"Kumagi T","year":"2008","unstructured":"Kumagi T, Heathcote EJ. Primary biliary cirrhosis. Orphanet J Rare Dis. 2008, 3:1. 10.1186\/1750-1172-3-1","journal-title":"Orphanet J Rare Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/2050640620919585","article-title":"Diagnosis and treatment of primary biliary cholangitis","volume":"8","author":"Laschtowitz A","year":"2020","unstructured":"Laschtowitz A, de Veer RC, Van der Meer AJ, Schramm C. Diagnosis and treatment of primary biliary cholangitis. United European Gastroenterol J. 2020, 8:667-74. 10.1177\/2050640620919585","journal-title":"United European Gastroenterol J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0929-6646(08)60133-3","article-title":"Primary biliary cirrhosis and IgG-kappa type multiple myeloma both respond well to vincristine, adriamycin and dexamethasone: is there a pathogenic relationship?","volume":"107","author":"Saka B","year":"2008","unstructured":"Saka B, Kalayoglu-Besisik S, Ozturk GB, Dogan O, Erten N. Primary biliary cirrhosis and IgG-kappa type multiple myeloma both respond well to vincristine, adriamycin and dexamethasone: is there a pathogenic relationship?. J Formos Med Assoc. 2008, 107:185-90. 10.1016\/S0929-6646(08)60133-3","journal-title":"J Formos Med Assoc"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.32.802","article-title":"Primary biliary cirrhosis associated with multiple myeloma","volume":"32","author":"Kaneko H","year":"1993","unstructured":"Kaneko H, Endo T, Saitoh H, Katsuta Y, Aramaki T, Hayakawa H. Primary biliary cirrhosis associated with multiple myeloma. Intern Med. 1993, 32:802-5. 10.2169\/internalmedicine.32.802","journal-title":"Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-141511","article-title":"The impact of S-Li-M criteria in myeloma in a real-life population: patient & disease characteristics, treatment and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)","volume":"136","author":"Ho PJ","year":"2020","unstructured":"Ho PJ, Moore EM, Wellard C, et al.. The impact of S-Li-M criteria in myeloma in a real-life population: patient & disease characteristics, treatment and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). Blood. 2020, 136:30-1. 10.1182\/blood-2020-141511","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/SPC.0000000000000467","article-title":"Mechanisms and treatment of bone pain in multiple myeloma","volume":"13","author":"Davies MP","year":"2019","unstructured":"Davies MP, Fingas S, Chantry A. Mechanisms and treatment of bone pain in multiple myeloma. Curr Opin Support Palliat Care. 2019, 13:408-16. 10.1097\/SPC.0000000000000467","journal-title":"Curr Opin Support Palliat Care"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i7.926","article-title":"Primary biliary cirrhosis: pathophysiology, clinical presentation and therapy","volume":"7","author":"Purohit T","year":"2015","unstructured":"Purohit T, Cappell MS. Primary biliary cirrhosis: pathophysiology, clinical presentation and therapy. World J Hepatol. 2015, 7:926-41. 10.4254\/wjh.v7.i7.926","journal-title":"World J Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07547.x","article-title":"Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols","volume":"145","author":"Nair B","year":"2009","unstructured":"Nair B, Waheed S, Szymonifka J, Shaughnessy JD Jr, Crowley J, Barlogie B. Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols. Br J Haematol. 2009, 145:134-7. 10.1111\/j.1365-2141.2008.07547.x","journal-title":"Br J Haematol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i25.7683","article-title":"Primary biliary cirrhosis: clinical and laboratory criteria for its diagnosis","volume":"21","author":"Reshetnyak VI","year":"2015","unstructured":"Reshetnyak VI. Primary biliary cirrhosis: clinical and laboratory criteria for its diagnosis. World J Gastroenterol. 2015, 21:7683-708. 10.3748\/wjg.v21.i25.7683","journal-title":"World J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01136.x","article-title":"Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes","volume":"102","author":"Silveira MG","year":"2007","unstructured":"Silveira MG, Talwalkar JA, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol. 2007, 102:1244-50. 10.1111\/j.1572-0241.2007.01136.x","journal-title":"Am J Gastroenterol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.616","article-title":"Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis","volume":"105","author":"Neuhauser M","year":"2010","unstructured":"Neuhauser M, Bjornsson E, Treeprasertsuk S, Enders F, Silveira M, Talwalkar J, Lindor K. Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis. Am J Gastroenterol. 2010, 105:345-53. 10.1038\/ajg.2009.616","journal-title":"Am J Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.03.019","article-title":"Prevalence of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome","volume":"9","author":"Bonder A","year":"2011","unstructured":"Bonder A, Retana A, Winston DM, Leung J, Kaplan MM. Prevalence of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol. 2011, 9:609-12. 10.1016\/j.cgh.2011.03.019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1381.028","article-title":"The clinical significance of IgA antimitochondrial antibodies in sera and saliva in primary biliary cirrhosis","volume":"1107","author":"Tanaka A","year":"2007","unstructured":"Tanaka A, Nezu S, Uegaki S, et al.. The clinical significance of IgA antimitochondrial antibodies in sera and saliva in primary biliary cirrhosis. Ann N Y Acad Sci. 2007, 1107:259-70. 10.1196\/annals.1381.028","journal-title":"Ann N Y Acad Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-038703","article-title":"CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms","volume":"109","author":"Zhan F","year":"2007","unstructured":"Zhan F, Colla S, Wu X, et al.. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood. 2007, 109:4995-5001. 10.1182\/blood-2006-07-038703","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810440","article-title":"Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants","volume":"360","author":"Hirschfield GM","year":"2009","unstructured":"Hirschfield GM, Liu X, Xu C, et al.. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med. 2009, 360:2544-55. 10.1056\/NEJMoa0810440","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07393-0","article-title":"HLA-DPA1 gene is a potential predictor with prognostic values in multiple myeloma","volume":"20","author":"Yang J","year":"2020","unstructured":"Yang J, Wang F, Chen B. HLA-DPA1 gene is a potential predictor with prognostic values in multiple myeloma. BMC Cancer. 2020, 20:915. 10.1186\/s12885-020-07393-0","journal-title":"BMC Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/102010-factors-explaining-the-coincidence-of-smoldering-multiple-myeloma-and-primary-biliary-cholangitis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:45:56Z","timestamp":1707507956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/102010-factors-explaining-the-coincidence-of-smoldering-multiple-myeloma-and-primary-biliary-cholangitis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,13]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.26830","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,13]]}}}